Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Judicialization of access to medicines in four Latin American countries: a comparative qualitative analysis.

Vargas-Pelaez CM, Rover MRM, Soares L, Blatt CR, Mantel-Teeuwisse AK, Rossi FA, Restrepo LG, Latorre MC, López JJ, Bürgin MT, Silva C, Leite SN, Farias MR.

Int J Equity Health. 2019 Jun 3;18(1):68. doi: 10.1186/s12939-019-0960-z.

2.

The double opioid crisis: A call for balance.

Vranken MJM, Schutjens MDB, Mantel-Teeuwisse AK.

Pharmacoepidemiol Drug Saf. 2019 Jan;28(1):1-3. doi: 10.1002/pds.4720. No abstract available.

PMID:
30656799
3.

Post-marketing dosing changes in the label of biologicals.

Minnema LA, Giezen TJ, Gardarsdottir H, Egberts TCG, Leufkens HGM, Mantel-Teeuwisse AK.

Br J Clin Pharmacol. 2019 Apr;85(4):715-721. doi: 10.1111/bcp.13843. Epub 2019 Feb 16.

4.

The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study.

Jacobs TG, Hilda Ampadu H, Hoekman J, Dodoo ANO, Mantel-Teeuwisse AK.

BMC Public Health. 2018 Dec 18;18(1):1384. doi: 10.1186/s12889-018-6285-9.

5.

Disease awareness campaigns in printed and online media in Latvia: cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards.

Leonardo Alves T, Poplavska E, Mezinska S, Salmane-Kulikovska I, Andersone L, Mantel-Teeuwisse AK, Mintzes B.

BMC Public Health. 2018 Nov 28;18(1):1322. doi: 10.1186/s12889-018-6202-2.

6.

Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study.

Postma DJ, De Smet PAGM, Gispen-de Wied CC, Leufkens HGM, Mantel-Teeuwisse AK.

Front Pharmacol. 2018 Oct 31;9:1243. doi: 10.3389/fphar.2018.01243. eCollection 2018.

7.

Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants.

Forslund T, Komen JJ, Andersen M, Wettermark B, von Euler M, Mantel-Teeuwisse AK, Braunschweig F, Hjemdahl P.

Stroke. 2018 Sep;49(9):2122-2128. doi: 10.1161/STROKEAHA.118.021990.

PMID:
30354995
8.

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs.

Vreman RA, Bouvy JC, Bloem LT, Hövels AM, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG.

Clin Pharmacol Ther. 2019 Mar;105(3):684-691. doi: 10.1002/cpt.1251. Epub 2018 Nov 8.

PMID:
30300938
9.

Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugs.

Bindraban AN, Rolvink J, Berger FA, van den Bemt PMLA, Kuijper AFM, van der Hoeven RTM, Mantel-Teeuwisse AK, Becker ML.

Int J Clin Pharm. 2018 Oct;40(5):1372-1379. doi: 10.1007/s11096-018-0692-y. Epub 2018 Jul 26.

PMID:
30051227
10.

Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study.

Bloem LT, Mantel-Teeuwisse AK, Leufkens HGM, De Bruin ML, Klungel OH, Hoekman J.

Clin Pharmacol Ther. 2019 Feb;105(2):426-435. doi: 10.1002/cpt.1169. Epub 2018 Aug 12.

PMID:
29969839
11.

Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries.

Bazargani YT, Ugurlu M, de Boer A, Leufkens HGM, Mantel-Teeuwisse AK.

BMC Cardiovasc Disord. 2018 Jun 25;18(1):126. doi: 10.1186/s12872-018-0858-5.

12.

Characteristics of drugs safety signals that predict safety related product information update.

Insani WN, Pacurariu AC, Mantel-Teeuwisse AK, Gross-Martirosyan L.

Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):789-796. doi: 10.1002/pds.4446. Epub 2018 May 24.

13.

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands.

van den Heuvel JM, Hövels AM, Büller HR, Mantel-Teeuwisse AK, de Boer A, Maitland-van der Zee AH.

Thromb J. 2018 Apr 18;16:7. doi: 10.1186/s12959-017-0156-y. eCollection 2018.

14.

Access to Strong Opioid Analgesics in the Context of Legal and Regulatory Barriers in Eleven Central and Eastern European Countries.

Vranken MJM, Mantel-Teeuwisse AK, Schutjens MDB, Scholten WK, Jünger S, Leufkens HGM.

J Palliat Med. 2018 Jul;21(7):963-969. doi: 10.1089/jpm.2017.0595. Epub 2018 Apr 6.

PMID:
29624475
15.

Change in parental knowledge, attitudes and practice of antibiotic use after a national intervention programme.

Ivanovska V, Angelovska B, van Dijk L, Zdravkovska M, Leufkens HG, Mantel-Teeuwisse AK.

Eur J Public Health. 2018 Aug 1;28(4):724-729. doi: 10.1093/eurpub/ckx240.

PMID:
29325065
16.

Renal function of MDR-TB patients treated with kanamycin regimens or concomitantly with antiretroviral agents.

Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Mengistu A, Mekonen TT, Leufkens HGM, Mantel-Teeuwisse AK.

Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1245-1250. doi: 10.5588/ijtld.16.0953.

PMID:
29297444
17.

Risk factors for QTc interval prolongation.

Heemskerk CPM, Pereboom M, van Stralen K, Berger FA, van den Bemt PMLA, Kuijper AFM, van der Hoeven RTM, Mantel-Teeuwisse AK, Becker ML.

Eur J Clin Pharmacol. 2018 Feb;74(2):183-191. doi: 10.1007/s00228-017-2381-5. Epub 2017 Nov 22.

PMID:
29167918
18.

Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.

Lepelaars LRA, Renda F, Pani L, Pimpinella G, Leufkens HGM, Trifirò G, Tafuri G, Mantel-Teeuwisse AK, Trotta F.

Br J Clin Pharmacol. 2018 Apr;84(4):738-763. doi: 10.1111/bcp.13454. Epub 2018 Jan 18.

19.

Availability, prices and affordability of UN Commission's lifesaving medicines for reproductive and maternal health in Uganda.

Kibira D, Kitutu FE, Merrett GB, Mantel-Teeuwisse AK.

J Pharm Policy Pract. 2017 Nov 15;10:35. doi: 10.1186/s40545-017-0123-9. eCollection 2017.

20.

Variability in market uptake of psychotropic medications in Europe reflects cultural diversity.

Hoebert JM, Mantel-Teeuwisse AK, Leufkens HGM, van Dijk L.

BMC Health Serv Res. 2017 Nov 6;17(1):702. doi: 10.1186/s12913-017-2649-6.

21.

Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study.

Ankrah DNA, Lartey M, Mantel-Teeuwisse AK, Leufkens HGM.

BMC Infect Dis. 2017 Oct 2;17(1):664. doi: 10.1186/s12879-017-2752-7.

22.

Age-Specific Antibiotic Prescribing and Adherence to Guidelines in Pediatric Patients in Primary Care.

Ivanovska V, Hek K, Mantel-Teeuwisse AK, Leufkens HGM, van Dijk L.

Pediatr Infect Dis J. 2018 Mar;37(3):218-223. doi: 10.1097/INF.0000000000001757.

PMID:
28859019
23.

Psychiatric medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study.

Fazeli Farsani S, Abdullah-Koolmees H, Souverein PC, de Boer A, Mantel-Teeuwisse AK.

Pediatr Diabetes. 2018 Feb;19(1):121-128. doi: 10.1111/pedi.12529. Epub 2017 Apr 24.

PMID:
28436135
24.

Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study.

Ivanovska V, Leufkens HG, Rademaker CM, Zisovska E, Pijnenburg MW, van Dijk L, Mantel-Teeuwisse AK.

Arch Dis Child. 2017 Apr;102(4):352-356. doi: 10.1136/archdischild-2016-311933. Epub 2017 Jan 24.

PMID:
28119403
25.

Barriers to access to opioid medicines for patients with opioid dependence: a review of legislation and regulations in eleven central and eastern European countries.

Vranken MJM, Mantel-Teeuwisse AK, Jünger S, Radbruch L, Scholten W, Lisman JA, Subataite M, Schutjens MDB.

Addiction. 2017 Jun;112(6):1069-1076. doi: 10.1111/add.13755. Epub 2017 Feb 8. Review.

PMID:
28087986
26.

Adverse events and patients' perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia.

Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK.

Patient Prefer Adherence. 2016 Nov 23;10:2369-2377. eCollection 2016.

27.

Improving the effectiveness of drug safety alerts to increase adherence to the guideline for gastrointestinal prophylaxis.

Lilih S, Pereboom M, van der Hoeven RT, Mantel-Teeuwisse AK, Becker ML.

Int J Med Inform. 2017 Jan;97:139-144. doi: 10.1016/j.ijmedinf.2016.10.002. Epub 2016 Oct 4.

PMID:
27919373
28.

Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.

Sagwa EL, Souverein PC, Ribeiro I, Leufkens HG, Mantel-Teeuwisse AK.

Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):1-8. doi: 10.1002/pds.4125. Epub 2016 Nov 20.

PMID:
27868278
29.

Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.

Tetteh RA, Nartey ET, Lartey M, Mantel-Teeuwisse AK, Leufkens HG, Yankey BA, Dodoo AN.

Drug Saf. 2016 Nov;39(11):1139-1149.

30.

Effects of over-the-counter sales restriction of antibiotics on substitution with medicines for symptoms relief of cold in Mexico and Brazil: time series analysis.

Santa-Ana-Tellez Y, Mantel-Teeuwisse AK, Leufkens HG, Wirtz VJ.

Health Policy Plan. 2016 Nov;31(9):1291-6. doi: 10.1093/heapol/czw066. Epub 2016 May 26.

PMID:
27229872
31.

Facilitators and barriers to antiretroviral therapy adherence among adolescents in Ghana.

Ankrah DN, Koster ES, Mantel-Teeuwisse AK, Arhinful DK, Agyepong IA, Lartey M.

Patient Prefer Adherence. 2016 Mar 15;10:329-37. doi: 10.2147/PPA.S96691. eCollection 2016.

32.

Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU.

Hoekman J, Klamer TT, Mantel-Teeuwisse AK, Leufkens HG, De Bruin ML.

Br J Clin Pharmacol. 2016 Jul;82(1):213-26. doi: 10.1111/bcp.12940. Epub 2016 Apr 22.

33.

Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference.

Vogler S, Zimmermann N, Ferrario A, Wirtz VJ, de Joncheere K, Pedersen HB, Dedet G, Paris V, Mantel-Teeuwisse AK, Babar ZU; Scientific Programme Committee of the 2015 PPRI Conference.

J Pharm Policy Pract. 2016 Mar 15;9:9. doi: 10.1186/s40545-016-0056-8. eCollection 2016.

34.

Antibiotic prescribing for children in primary care and adherence to treatment guidelines.

Ivanovska V, Hek K, Mantel Teeuwisse AK, Leufkens HG, Nielen MM, van Dijk L.

J Antimicrob Chemother. 2016 Jun;71(6):1707-14. doi: 10.1093/jac/dkw030. Epub 2016 Mar 5.

PMID:
26945710
35.

Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries.

Vranken MJ, Lisman JA, Mantel-Teeuwisse AK, Jünger S, Scholten W, Radbruch L, Payne S, Schutjens MH.

Lancet Oncol. 2016 Jan;17(1):e13-22. doi: 10.1016/S1470-2045(15)00365-4. Epub 2015 Dec 23. Review.

PMID:
26758755
36.

Extensions of indication throughout the drug product lifecycle: a quantitative analysis.

Langedijk J, Whitehead CJ, Slijkerman DS, Leufkens HG, Schutjens MH, Mantel-Teeuwisse AK.

Drug Discov Today. 2016 Feb;21(2):348-55. doi: 10.1016/j.drudis.2015.11.009. Epub 2015 Dec 2. Review.

PMID:
26657087
37.

Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.

Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK.

BMC Pharmacol Toxicol. 2015 Dec 10;16:36. doi: 10.1186/s40360-015-0036-7.

38.

Characteristics of product recalls of biopharmaceuticals and small-molecule drugs in the USA.

Ebbers HC, de Tienda NF, Hoefnagel MC, Nibbeling R, Mantel-Teeuwisse AK.

Drug Discov Today. 2016 Apr;21(4):536-9. doi: 10.1016/j.drudis.2015.10.020. Epub 2015 Nov 11.

PMID:
26552336
39.

Licensing failure in the European decentralised procedure.

Langedijk J, Ebbers HC, Mantel-Teeuwisse AK, Kruger-Peters AG, Leufkens HG.

Eur J Pharm Sci. 2016 May 25;87:47-51. doi: 10.1016/j.ejps.2015.10.014. Epub 2015 Oct 19.

PMID:
26493584
40.

Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.

Vermeer NS, Straus SM, Mantel-Teeuwisse AK, Hidalgo-Simon A, Egberts AC, Leufkens HG, De Bruin ML.

Clin Pharmacol Ther. 2015 Nov;98(5):542-50. doi: 10.1002/cpt.207. Epub 2015 Sep 8.

PMID:
26347128
41.

Essential medicines for breast cancer in low and middle income countries.

Bazargani YT, de Boer A, Schellens JH, Leufkens HG, Mantel-Teeuwisse AK.

BMC Cancer. 2015 Aug 18;15:591. doi: 10.1186/s12885-015-1583-4.

42.

Reply to "decrease in penicillin sales in Brazil after over-the-counter restrictions".

Santa-Ana-Tellez Y, Mantel-Teeuwisse AK, Leufkens HG, Wirtz VJ.

Antimicrob Agents Chemother. 2015 Sep;59(9):5864. doi: 10.1128/AAC.01128-15. No abstract available.

43.

Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.

Tetteh RA, Nartey ET, Lartey M, Mantel-Teeuwisse AK, Leufkens HG, Nortey PA, Dodoo AN.

BMC Public Health. 2015 Jun 20;15:573. doi: 10.1186/s12889-015-1928-6.

44.

Drug repositioning and repurposing: terminology and definitions in literature.

Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH.

Drug Discov Today. 2015 Aug;20(8):1027-34. doi: 10.1016/j.drudis.2015.05.001. Epub 2015 May 11. Review.

PMID:
25975957
45.

Chronic comorbidities in children with type 1 diabetes: a population-based cohort study.

Fazeli Farsani S, Souverein PC, van der Vorst MM, Knibbe CA, de Boer A, Mantel-Teeuwisse AK.

Arch Dis Child. 2015 Aug;100(8):763-8. doi: 10.1136/archdischild-2014-307654. Epub 2015 Apr 15.

PMID:
25877155
46.

Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands.

Fazeli Farsani S, Souverein PC, Overbeek JA, van der Vorst MM, Knibbe CA, Herings RM, de Boer A, Mantel-Teeuwisse AK.

Br J Clin Pharmacol. 2015 Aug;80(2):294-303. doi: 10.1111/bcp.12608. Epub 2015 May 20.

47.

Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study.

Sagwa EL, Mantel-Teeuwisse AK, Ruswa NC.

J Pharm Policy Pract. 2014 Oct 21;7(1):14. doi: 10.1186/2052-3211-7-14. eCollection 2014.

48.

Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries.

Leopold C, Mantel-Teeuwisse AK, Vogler S, Valkova S, de Joncheere K, Leufkens HG, Wagner AK, Ross-Degnan D, Laing R.

Bull World Health Organ. 2014 Sep 1;92(9):630-640D. doi: 10.2471/BLT.13.129114. Epub 2014 Jun 16.

49.

Increasing trends in the incidence and prevalence rates of type 1 diabetes among children and adolescents in the Netherlands.

Fazeli Farsani S, Souverein PC, van der Vorst MM, Knibbe CA, Herings RM, de Boer A, Mantel-Teeuwisse AK.

Pediatr Diabetes. 2016 Feb;17(1):44-52. doi: 10.1111/pedi.12232. Epub 2014 Nov 7.

PMID:
25377748
50.

Traceability of biologicals: present challenges in pharmacovigilance.

Vermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, Egberts TC, De Bruin ML.

Expert Opin Drug Saf. 2015 Jan;14(1):63-72. doi: 10.1517/14740338.2015.972362. Epub 2014 Nov 5. Review.

PMID:
25369769

Supplemental Content

Loading ...
Support Center